フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Shield Therapeutics PLC 20 June 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Results of 2024 Annual General...
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by A ...
Shield Therapeutics PLC 28 May 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Shield's Korean Partner files New...
Shield Therapeutics PLC 10 May 2024 Shield Therapeutics plc ("Shield" or...
The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not sep ...
Shield Therapeutics PLC 30 April 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Business Update for Q1 2024 and...
Shield Therapeutics PLC 16 April 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Notice of Results Investor...
Shield Therapeutics PLC on Wednesday said that it was expecting stellar results for 2023, but this success was oversh ...
Shield Therapeutics PLC 21 February 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Unaudited Full Year Trading...
cs PLC - Commercial-stage pharmaceutical company focused on iron deficiency product Accrufer - Hires Santosh Shanbhag ...
Shield Therapeutics PLC 09 January 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group"...
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by ...
Shield Therapeutics PLC 07 December 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Q3 2023...
Shield Therapeutics PLC 27 November 2023 Shield Therapeutics plc ("Shield Therapeutics" or the "Company") PDMR Transaction...
cs PLC - commercial-stage pharmaceutical company focusing on its iron deficiency product Accrufer - Chief Financial Of ...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約